Amgen 2009 Annual Report Download - page 113

Download and view the complete annual report

Please find page 113 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

Exhibit No. Description
10.35 Confirmation of OTC Warrant Transaction, dated February 14, 2006, to Amgen Inc. from Morgan
Stanley & Co. International Limited for warrants maturing in 2011. (Filed as an exhibit to
Form 10-K for the year ended December 31, 2005 on March 10, 2006 and incorporated herein by
reference.)
10.36 Purchase Agreement, dated May 24, 2007, among Amgen Inc., Morgan Stanley & Co.
Incorporated, Merrill Lynch, Pierce, Fenner & Smith Incorporated and the Initial Purchasers
Names in Schedule A thereof. (Filed as an exhibit to Form 10-Q for the quarter ended June 30,
2007 on August 9, 2007 and incorporated herein by reference.)
10.37 Purchase Agreement, dated May 29, 2007, between Amgen Inc. and Merrill Lynch International.
(Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2007 on August 9, 2007 and
incorporated herein by reference.)
10.38 Collaboration Agreement, dated July 11, 2007, between Amgen Inc. and Daiichi Sankyo Company
(with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the
quarter ended September 30, 2007 on November 9, 2007 and incorporated herein by reference.)
10.39 Credit Agreement, dated November 2, 2007, among Amgen Inc., with Citicorp USA, Inc., as
administrative agent, Barclays Bank PLC, as syndication agent, Citigroup Global Markets, Inc.
and Barclays Capital, as joint lead arrangers and joint book runners, and the other banks party
thereto. (Filed as an exhibit to Form 8-K filed on November 2, 2007 and incorporated herein by
reference.)
10.40 Amendment No. 1, dated May 18, 2009, to the Credit Agreement dated November 2, 2007, among
Amgen Inc., with Citicorp USA, Inc., as administrative agent, Barclays Bank PLC, as syndication
agent, Citigroup Global Markets, Inc. and Barclays Capital, as joint lead arrangers and joint book
runners, and the other banks party thereto. (Filed as an exhibit to Form 10-Q for the quarter ended
June 30, 2009 on August 10, 2009 and incorporated herein by reference.)
10.41 Multi-product License Agreement with Respect to Japan between Amgen Inc. and Takeda
Pharmaceutical Company Limited dated February 1, 2008 (with certain confidential information
deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on
May 12, 2008 and incorporated herein by reference.)
10.42 License Agreement for motesanib diphosphate between Amgen Inc. and Takeda Pharmaceutical
Company Limited dated February 1, 2008 (with certain confidential information deleted
therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12,
2008 and incorporated herein by reference.)
10.43 Supply Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited dated
February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to
Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by
reference.)
10.44 Sale and Purchase Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited
dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed as an
exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated
herein by reference.)
10.45 Variable Term Accelerated Share Repurchase Transaction dated May 28, 2008, between Amgen
Inc. and Lehman Brothers, Inc. acting as Agent Lehman Brothers OTC Derivatives Inc., acting as
Principal. (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2009 on August 8, 2008
and incorporated herein by reference.)
101